Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11248054 Anti-IL1RAP antibodies and antibody drug conjugates

Patent 11248054 was granted and assigned to Bluefin Biomedicine on February, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
‌
Bluefin Biomedicine
Date Filed
June 12, 2018
Date of Patent
February 15, 2022
Patent Applicant
‌
Bluefin Biomedicine
Patent Application Number
16620386
Patent Citations
‌
US Patent 10471086 Treatment of chronic obstructive pulmonary disease (COPD)
‌
US Patent 10519230 Nucleic acids encoding IL-33 antibodies
‌
US Patent 10544212 Anti-IL-33 antibodies, compositions, methods and uses thereof
‌
US Patent 10562971 Method of detection of IL1RAP on cells expressing the protein
‌
US Patent 10588298 Humanized IL-4 and IL-4Rα animals
‌
US Patent 10668150 IL33 form, mutated forms of IL33, antibodies, assays and methods of using the same
‌
US Patent 10669594 Compositions and methods for detecting a biological contaminant
‌
US Patent 10723795 Anti-interleukin-33 antibodies and uses thereof
‌
US Patent 10752692 Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof
‌
US Patent 10752703 Anti-tryptase antibodies, compositions thereof, and uses thereof
•••
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11248054
Patent Primary Examiner
‌
Elly-Gerald Stoica

Find more entities like US Patent 11248054 Anti-IL1RAP antibodies and antibody drug conjugates

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.